% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Michels:142489,
      author       = {J. Michels and N. Becker and S. Suciu and I. Kaiser and A.
                      Benner$^*$ and Z. Kosaloglu-Yalcin and S. Agoussi and N.
                      Halama and M. Pawlita$^*$ and T. Waterboer$^*$ and S.
                      Eichmüller$^*$ and D. Jäger$^*$ and A. M. M. Eggermont and
                      I. Zörnig},
      title        = {{M}ultiplex bead-based measurement of humoral immune
                      responses against tumor-associated antigens in stage {II}
                      melanoma patients of the {EORTC}18961 trial.},
      journal      = {OncoImmunology},
      volume       = {7},
      number       = {6},
      issn         = {2162-402X},
      address      = {Abingdon},
      publisher    = {Taylor $\&$ Franics},
      reportid     = {DKFZ-2019-00208},
      pages        = {e1428157 -},
      year         = {2018},
      abstract     = {Purpose: Determine the prognostic and predictive
                      significance of tumor associated antigen (TAA)-specific
                      serum antibodies in melanoma patients of a large adjuvant
                      vaccination phase III trial. Patients and methods: Serum IgG
                      antibodies were measured against a panel of 43 antigens by a
                      bead-based multiplex assay in 970 stage II melanoma patients
                      of the EORTC18961 trial, evaluating adjuvant ganglioside
                      GM2-KLH/QS-21 vaccination versus observation. Primary end
                      point was relapse-free survival (RFS). Patients' sera at
                      baseline, after 12 and 48 weeks of study treatment and at
                      the last available time point (at recurrence/remission) were
                      evaluated. Results: Prognostic clinical variables are
                      gender, surgical confirmation of lymph node-negative status,
                      Breslow thickness and ulceration of the primary. Prognostic
                      spontaneous antibody responses were associated with a
                      significant dismal (GM2, $Rhod_E2,$ SSX2) or good prognosis
                      (CyclinB1, SCYE1v1) for RFS, distant metastasis-free (DMFS)
                      or overall survival (OS). Predictive spontaneous antibody
                      responses based on significant interaction with treatment
                      were RhodN p = 0.02, Rab38 p = 0.04 for RFS, RhodE2 p =
                      0.006, Recoverin p = 0.04 for DMFS and RhodE2 p = 0.003;
                      Recoverin p = 0.04, NA17.A p = 0.04, for OS respectively.
                      The subgroups of patients according to antibody responses
                      for RFS were determined for RhodN sero-negative (n = 849, HR
                      = 1.07, p = 0.6); RhodN sero-positive (n = 121,HR = 0.42, p
                      = 0.01) and Rab38 sero-negative (n = 682, HR = 1.12, p =
                      0.42), Rab38 sero-positive (n = 288, HR = 0.65, p = 0.04)
                      patients respectively. Conclusion: We identified prognostic
                      serum antibody responses against TAA in stage II melanoma
                      patients. A set of antibody responses correlated with a
                      beneficial outcome for GM2 vaccination.},
      cin          = {C060 / D120 / F020 / F022 / G183 / G182},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331 / I:(DE-He78)D120-20160331 /
                      I:(DE-He78)F020-20160331 / I:(DE-He78)F022-20160331 /
                      I:(DE-He78)G183-20160331 / I:(DE-He78)G182-20160331},
      pnm          = {314 - Tumor immunology (POF3-314)},
      pid          = {G:(DE-HGF)POF3-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29872552},
      pmc          = {pmc:PMC5980408},
      doi          = {10.1080/2162402X.2018.1428157},
      url          = {https://inrepo02.dkfz.de/record/142489},
}